Martin David Harp

The contract research organization and technology solution is for the execution of ophthalmology clinical trials.

MK-3000, formally known as EYE103, is an investigational, potentially first-in-class tetravalent, tri-specific antibody that acts as an agonist of the Wnt signaling pathway.

The trial is evaluating phentolamine ophthalmic solution 0.75% for the treatment of presbyopia.

The non-diffractive, aspheric IOLs are the second generation of BVI’s ISOPURE family

The one-time intravitreally delivered gene therapy is for the treatment of retinitis pigmentosa (RP).

PAS-nomacopan is a long-acting bispecific inhibitor of C5 and leukotriene B4 for intravitreal treatment of geographic atrophy (GA).

The agreement with give Apotex exclusive rights in Canada for the commercialization of APP13007.

Results suggest higher exposures to lower temperatures and certain air pollutants could result in worsened ocular symptoms and increased tear osmolarity.

The positive opinion from the CHMP comes with the recommendation that Vevizye be granted marketing authorization for the treatment of dry eye disease in the European Union.

The trial will evaluate repeat dosing of axitinib intravitreal implant, (AXPAXLI) for the treatment of patients with wet AMD.

The trial will evaluate VRDN-001, an intravenously delivered monoclonal antibody that acts as a full antagonist of the insulin-like growth factor-1 receptor (IGF-1R).

The nOCT allows for detailed visualization of the brain's vascular anatomy.

Scott Xiao, co-founder and CEO of Luminopia, sat with Ophthalmology Times to discuss the PUPiL Registry and how the VR treatment for children with amblyopia works and can revolutionize amblyopia treatment.

4D-150 Is being evaluated in wet age-related macular degeneration (AMD).

This marks 21 years in a row the hospital has been top-ranked by the US News & World Report in the field of ophthalmology.

AAV204 is a novel adeno-associated virus (AAV) capsid from the AIM capsid library licensed by Abeona from the University of North Carolina at Chapel Hill.

The primary endpoint will be pain improvement as measured by visual analogue scale (VAS) compared to placebo.

Most respondents were unsure of how to seek treatment and see dry eye as something that must be learned to live with.

The company states this will enable movement toward US approval

The funding will go toward the continued clinical development of the company’s lead asset, AGTC-501 (laruparetigene zovaparvovec)

The deal included a total upfront consideration of $81 million, including a cash payment of approximately $65 million.

Apellis plans to seek re-examination, with a final opinion expected in fourth quarter of 2024.

The biosimilar was approved for treating patients with age-related neovascular (wet) macular degeneration (nAMD) and other serious retinal diseases.

Ashley Brissette, MD, MSc, FRCSC, team ophthalmologist for the New York Rangers sat down to talk about eye injuries in hockey and other professional sports, as well as advancements in prevention and treatment for the players.

4D-175 will be evaluated in the GAZE clinical trial, an upcoming phase 1, open-label trial.

Under the new policy, grant-making entities will be encouraged to fund post-market research investigating pharmacodynamics and pharmacokinetics for generic drugs that did not adequately enroll women, and sexual and gender minority populations in their clinical trials.

The trial is designed to enable a resubmission of a New Drug Application to the US FDA for reproxalap after receiving a Complete Response Letter last year.

Two randomized, double-masked, placebo-controlled, Phase 3 trials named REVEAL-1 and REVEAL-2 are expected to start in August 2024.

All R&D for the drug will stop after the Phase 2a clinical trial failed to meet its primary endpoint of lowering IOP in patients with primary open-angle glaucoma.

MELT-300 is a non IV, non-opioid tablet that combines fixed doses of midazolam (3mg) and ketamine (50mg).